GTC BIOTHERAPEUTICS ANNOUNCES TIME CHANGE FOR WEBCAST OF CORPORATE PRESENTATION AT SG COWEN & CO. 6TH ANNUAL GLOBAL HEALTH CARE CONFERENCE Framingham, Mass., November 4, 2005-- GTC Biotherapeutics, Inc. (Nasdaq: GTCB) ("GTC") announced today a time change for the presentation to be given by Geoffrey Cox, Ph.D., Chairman and CEO of the Company, at the SG Cowen & Co. 6th Annual Global Health Care Conference. The presentation is now scheduled for 11:30 a.m. Central European Time (5:30 a.m. Eastern Time) on Thursday, November 10, 2005. The conference is being held at the Hilton Diagonal Mar, Barcelona, Spain. The presentation will be webcast live and can be accessed by logging onto www.gtc-bio.com. The replay can be accessed from this same website and will be available within 24 hours of the presentation. GTC Biotherapeutics is a leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC's lead program is ATrynŽ, its recombinant form of human antithrombin. A Market Authorization Application is under review by the European Medicines Agency for the use of ATrynŽ in patients with a hereditary antithrombin deficiency. In addition to the ATrynŽ program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine. In its external programs, GTC's technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult to produce in significant quantities from conventional recombinant production systems. One of the external programs is in clinical trials with a transgenically produced product. Additional information is available on the GTC web site, http://www.gtc-bio.com. CONTACT: GTC Biotherapeutics, Inc. Thomas E. Newberry Vice President, Corporate Communications (508) 370-5374 Feinstein Kean Healthcare Francesca DeVellis (investors) (617) 577-8110 Back to 2005 Archives
	Copyright 2006 GTC Biotherapeutics, All Rights Reserved